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ABSTRACT
Background and Objectives: Left ventricular (LV) remodeling is a heterogeneous process, involving both infarcted and 
non-infarcted zones, which affects wall thickness and chamber size, shape and function. Subjects and Methods: A total of 
758 consecutive patients (62.8±12.0 years, 539 males) with acute myocardial infarction (AMI), who were examined by echo-
cardiography at admission and after 6 months. An increase in LV end-diastolic volume index >10% was defined as a progres-
sive LV dilation. They were divided into two groups according to the extent of progressive LV dilatation during 6 months. 
Group I with progressive LV dilatation (n=154, 61.4±11.0 years, 110 males) vs. group II without LV dilatation (n=604, 
64.1±12.0 years, 429 males). Results: The age and gender were no significant differences between two groups. The levels of 
glucose, creatinine, maximal creatine kinase (CK), CK-MB, troponin T and I were significantly increased in group I than in 
group II (p<0.05). Low ejection fraction (EF) and high wall motion score index (WMSI) were more common in group I than 
in group II (p<0.05). The presence of dyslipidemia {odds ratio (OR); 1.559, confidence interval (CI); 1.035-2.347, p=0.03}, low 
EF less than 45% (OR; 3.328, CI 2.099-5.276, p<0.01) and high WMSI above 1.5 (OR; 3.328, CI 2.099-5.276, p<0.01) were sig-
nificant independent predictors of progressive LV dilatation by multivariate analysis. Conclusion: Dyslipidemia, decreased 
systolic function and high WMSI were independent predictors of LV remodeling process in patients with AMI. (Korean 
Circ J 2011;41:124-129)
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Introduction
Left ventricle (LV) remodeling following acute myocardial 
infarction (AMI) is a major predictor of morbidity and mor-
tality for overt congestive heart failure (CHF) and life threat-
ening arrhythmia.
1) LV remodeling is a heterogeneous pro-
cess, involving both infarcted and non-infarcted myocardium, 
which affects wall thickness and chamber size, shape and func-
tion. LV dilatation after MI procedures reduce exercise per-
formance and it plays a role in the development of chronic he-
art failure.
2)3) Post-infarction remodeling has been arbitrarily 
divided into an early phase (within 72 hours), and a late phase 
(beyond 72 hours). The early phase involves expansion of the 
infarct zone, which may result in early ventricular rupture or 
aneurysm formation. Late ventricular remodeling involves 
the LV globally and is associated with time-dependent dila-
tation, distortion of ventricular shape, and mural hypertro-
phy.
4) Patients who develop LV dilatation following AMI have 
significantly reduced survival.
5)6) It has been reported that 
LV volume is the single most important predictor of survival 
in patients with coronary heart disease.
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acute MI stimulates the interaction of a number of factors, 
such as loss of contractile elements, activation of circulating 
neurohormones and patency of the infarct-related artery (IRA), 
initial infarction size and LV size to normalize wall stress.
8)9) 
It can begin very soon after AMI and, if not attenuated or re-
versed by intervention, has a poor prognosis.
10) 
The purpose of this study was to assess the associated fac-
tors with LV remodeling in the first 6 months following MI, 
and to define the clinical, biochemical, echocardiographic and 
angiographic predictors of LV dilatation after AMI.
Subjects and Methods
Study population
A total of 758 consecutive patients (62.8±12.0 years, 539 
males) with AMI were examined by echocardiography at ad-
mission and after 6 months. An increase in left ventricular end-
diastolic volume index (LVEDVI) more than 10% was defin-
ed as progressive LV dilation. They were classified into two gr-
oups according to the extent of progressive LV dilatation in 6 
months. Group I with progressive LV dilatation (n=154, 61.4± 
11.0 years, 110 males 44 females) vs. group II without LV di-
latation (n=604, 63.1±1.02 years, 429 males 175 females).
 
Definition of hypertension, diabetes, dyslipidemia 
and myocardial infarction
Subjects were considered to be hypertensive if their blood 
pressure was more than 140≥90 mmHg as Joint National Com-
mittee VII
11) or if they were on treatment for hypertension. The 
American Diabetes Association criteria
12) were used to define 
diabetes (DM). We considered a subject to have DM when the 
fasting plasma glucose levels were more than 126 mg/dL in 2 
consecutive assessments, or if they were on treatment for DM. 
Dyslipidemia was diagnosed according to the 2004 update of 
the National Cholesterol Education Program guidelines.
13) Ac-
cording to these guidelines, high level of low density lipo-
protein-cholesterol (LDL-C) more than 160 mg/d, low high den-
sity lipoprotein-cholesterol (HDL-C) less than 40 mg/dL and 
high triglycerides more than 150 mg/dL were included.
14) 
The presence of ST-segment elevation MI was determined 
by more than 30 minutes of continuous chest pain, a new ST-
segment elevation more than 2 mm on at least two contigu-
ous electrocardiographic leads, creatine kinase (CK)-MB or 
troponin more than 3 times normal.
15) The presence of non-
ST-segment elevation MI was diagnosed by chest pain and a 
positive cardiac biomarker without new ST-segment eleva-
tion.
16) Infarct-related arteries were identified using a combi-
nation of electrocardiographic findings, LV wall motion ab-
normalities on two-dimensional echocardiography and coro-
nary angiography. Family history means early cardiovascular 
disease in direct relatives. Hospital records of patients were re-
viewed to obtain information on clinical demographics.
Measurement of serum biomarkers
Serum N-terminal pro-B-type natriuretic peptide (NT-pro-
BNP) was measured using the electrochemiluminescence 
sandwich immunoassay method for NT-pro-BNP with an 
Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Ger-
many). This method has high sensitivity and specificity, and 
large detection range. The analytic range of the NT-pro-BNP 
assay extends from 5 to 35,000 pg/mL. High sensitivity C-re-
active protein (hs-CRP) was measured by immunoturbidime-
tric CRP-Latex (II) high-sensitivity assay using an Olympus 
5431 autoanalyzer.
 
Measurement of progressive left ventricular 
dilatation
Two-dimensional, M-mode echocardiography and Dop-
pler ultrasound examination were performed with GE Vivid 
7 Ultrasound (General Electronic Healthcare, Vingmed, Hor-
ten Norway) with a 2.5 MHz probe. Image-Point at the time 
of initial admission and at 6 months after MI. LV volume and 
ejection fraction (EF) were measured using the Simpson’s 
formula.
17) LV volume indices were obtained by dividing the 
volume by the body surface area. The mean values of three me-
asurements of the technically best cardiac cycles were taken 
from each examination performed by two independent inter-
observers. Intra-observer and inter-observer variabilities of 
the Simpson’s method were 4±5% and 5±4% (absolute dif-
ference divided by mean value of measurement). In each pa-
tient the wall motion score index (WMSI) was derived. The 
LV was divided according to a 17-segment model.
18) In each seg-
ment wall motion was scored from 1 (normal) to 4 (dyskine-
tic). An increase in LVEDVI >10% between initial and 6 month 
follow up was considered as a progressive LV dilatation pattern.
 
Statistical analysis
The Statistical Package for Social Sciences for Windows, 
version 15.0 (Chicago, IL, USA) was used for all analysis. For 
each parameter mean, median and standard deviation were 
calculated. Statistical significance between means for differ-
ent groups was calculated by the non-parametrical Wilcox-
on signed rank test. Statistical significance between frequen-
cies was calculated by the chi square test with Yates correction 
or, if the expected value was less than 5, by Fisher’s exact test. 
Relative risk and confidence interval (CI) were also calculat-
ed. A p of less than 0.05 was required to reject the null hypo-
thesis. The variables that were significant in univariate anal-
ysis were entered into the multivariate models.
 
 Results
Baseline clinical characteristics
The baseline characteristics are summarized in Table 1. 
Age and gender exhibited no significant differences between 126   LV Remodeling After AMI
two groups. The prevalence of dyslipidemia was higher in 
group I than group II (p<0.05). The proportion of ST-segment 
elevation MI was more frequent in group I than in group II (p< 
0.05). There was no difference between the groups with respect 
to the initial vital sign or Killip class.
Biochemical, echocardiographic and coronary 
angiographic parameter associated 
with progressive left ventricular dilatation 
The levels of glucose, maximal CK, CK-MB, troponin-T and 
troponin-I were significantly increased in group I compared 
to group II (p<0.05) (Table 2). LV end-diastolic and systolic di-
mension, interventricular septal thickness, posterior wall th-
ickness were increased in group II compared to group I at ad-
mission. However, 6-month follow up echocardiography sh-
owed reversal of LV size mentioned above. LV dimension and 
volume were more increased in group I compared to group II 
at 6 months (p<0.05). Although the mean valve of EF and to-
tal wall motion score (TWMS) at admission were not signif-
icantly different between the groups, the percentage of low 
EF (<45%) and high WMSI (≥1.5) were higher in group I than 
in group II (p<0.05). Six-month EF and wall motion score were 
deteriorated compared to the initial score (p<0.05) (Table 3). 
Changes in LV volume at admission and at 6 months were 
significantly increased in group I, but not in group II (Fig. 1A). 
Fig. 1B showed decreased EF in group I and no significant ch-
ange in group II during the 6-month period. Serial changes 
of TWMS at admission and at 6 months are illustrated in Fig. 
1C. It was decreased TWMS in group II and no significant 
Table 1. Baseline clinical characteristics of the patients
 
Group I
(n=154)
Group II
(n=604)
p
Age (years) 061.4±12.0 63.17±12.0 0.127
Gender (male, %) 110 (71.4) 429 (71.0) 0.504
BMI (kg/m
2) 24.3±3.3 24.12±3.10 0.401
SBP (mmHg) 133.2±27.4 134.1±28.3 0.669
DBP (mmHg) 082.9±15.9 083.9±17.0 0.524
HR (/minute) 0.76±7.0 0.75±8.1 0.627
Risk factors (%)  
    Hypertension 068 (44.1) 279 (46.1) 0.359
    Diabetes mellitus 039 (25.3) 154 (25.4) 0.140
    Dyslipidemia 098 (63.6) 324 (53.6) 0.023
    Smoking 074 (48.0) 251 (41.5) 0.087
Family history (%) 07 (4.5) 33 (5.5) 0.714
Diagnosis (STEMI) (%) 111 (72.0) 373 (61.7) 0.010
Killip class (≥2) (%) 033 (21.4) 115 (19.0) 0.738
Cardiogenic shock (%) 10 (6.4) 32 (5.3) 0.341
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, HR: heart rate, STEMI: ST-segment elevation myo-
cardial infarction
Table 2. Biochemical parameters of left ventricular dilatation in 
patients with acute myocardial infarction
 
Group I
(n=154)
Group II
(n=604)
p
Glucose (mg/dL) 182.94±85.0 168.27±74.3 0.031
Creatinine (mg/dL) 001.07±0.69 001.15±1.09 0.412
Creatinine kinase (IU/L) 0.2145±2312 0.1342±1668 <0.001
Creatinine kinase MB (IU/L) 0126.8±132 000.82±100 <0.001
Troponine I (µg/L) 0068.1±71.94 0049.2±114.76 0.004
Troponine T (µg/L) 007.15±7.23 005.02±6.38 <0.001
Total cholesterol (mg/dL) 0183.9±45.27 0179.5±40.36 0.246
Tryglyceride (mg/dL) 0117.2±53.17 0116.4±67.19 0.825
HDL-C (mg/dL) 0050.3±43.74 0046.5±24.39 0.064
LDL-C (mg/dL) 121.11±39.7 0117.0±35.81 0.195
hs-CRP (mg/L) 002.43±2.74 002.12±3.95 0.366
NT-proBNP (pg/mL) 2947.8±6708 2311.5±5134 0.230
HDL-C: high density lipoprotein-cholesterol, LDL-C: low density li-
poprotein-cholesterol, hs-CRP: high sensitivity C-reactive protein, 
NT-pro-BNP: N-terminal pro B natriuretic peptide
Table 3. Echocardiographic parameters of left ventricular dilata-
tions in the patients with acute myocardial infarction
 
Group I
(n=154)
Group II
(n=604)
p
LV end-diastolic dimension (mm) 47.9±5.0 051.9±18.8 0.009
LV end-systolic dimension (mm) 32.8±5.9 35.1±6.7 <0.001
LVEDV (mm
3) 155.6±42.2 177.3±37.8 0.002
LVESV (mm
3) 073.5±39.1 083.5±34.0 0.037
Interventricular septum (mm) 10.3±2.2 09.6±1.8 0.002
Posterior wall thickness (mm) 10.1±2.5 09.6±2.0 0.037
EF (%) 057.6±11.7 058.6±11.9 0.339
EF <45% (%) 43 (31.8) 130 (21.5) 0.034
Ascending aorta diameter (mm) 30.8±3.9 31.7±4.3 0.333
LA dimension (mm) 37.8±6.8 038.3±13.9 0.735
E (m/sec) 00.64±0.21 00.90±0.53 0.627
A (m/sec) 01.03±0.19 00.86±1.65 0.606
E/A 00.86±0.37 00.94±0.47 0.122
Deceleration time (sec) 0183±54.6 0.187±61.1 0.598
E’ (cm/sec) 0.059±0.01 0.064±0.04 0.266
A’ (cm/sec) 0.093±0.02 00.18±1.73 0.658
S’ (cm/sec) 0.32±0.8 0.08±0.1 0.585
E/E’ 11.2±5.3 11.5±7.90. 0.643
Wall motion score 22.7±5.2 22.0±5.6 0.213
Wall motion score index ≥1.5 (%) 49 (31.8) 146 (24.1) 0.032
6 month LVEDV (mm
3) 197.7±48.1 101.1±85.2 <0.001
6 month LVESV (mm
3) 101.2±48.2 046.1±44.0 <0.001
6 month EF (%) 047.9±10.4 52.7±9.3 0.006
6 month E/E’ 11.5±5.6 10.5±5.9 0.108
6 month wall motion score 21.8±5.5 19.7±4.4 <0.001
LV: left ventricle, EF: ejection fraction, LA: left atrium; LVEDV: LV 
end diastolic volume, LVESV: LV end systolic volumeHyun Ju Yoon, et al.   127
change in group I.
A total of 71 patients were treated with thrombolytic ther-
apy in this patient group. Thrombolytic therapy did not affect 
progressive LV dilatation. There were no significant differenc-
es between groups in the stenting rate, involved vessel num-
ber, IRA, post-PCI thrombolysis in myocardial infarction 
(TIMI) flow and the percentage of restenosis on follow-up 
coronary angiography. The percentage of low TIMI flow (≤2) 
was higher in group I than in group II (p<0.5). Medication his-
tory of angiotensin converting enzyme inhibitor, angioten-
sin receptor blocker, statin, and beta blocker did not affect pro-
gressive LV dilatation (Table 4).
Independent predictors of progressive left 
ventricular dilatation
The presence of dyslipidemia {odd ratio (OR); 1.559, CI; 
1.035-2.347, p=0.03}, low LVEF less than 45% (OR; 3.328, CI 
2.099-5.276, p<0.01) and high WMSI above 1.5 (OR; 3.328, CI 
2.099-5.276, p<0.01) were significant independent predictors 
of progressive LV dilatation by multivariate analysis (Table 5). 
Discussion
The acute loss of myocardium in AMI results in an abrupt 
increase in loading conditions that induces a unique pattern 
of remodeling, involving the infarct border zone and remote 
non-infarcted myocardium.
19) Myocyte necrosis and the resul-
tant increase in load trigger a cascade of biochemical intra-
cellular signaling processes that indicate and subsequently 
modulates reparative changes, including dilatation, hypertro-
phy, and the formation of a discrete collagen scar. Ventricular 
remodeling may continue for weeks or months until the dis-
tending forces are counterbalanced by the tensile strength of 
the collagen scar. Failure to normalize increased wall stresses 
results in progressive dilatation, recruitment of border zone 
myocardium into the scar, and deterioration in contractile 
function. This balance is determined by the size, location, 
and transmurality of the infarct, the extent of myocardial stun-
ning, the patency of the IRA, and local tropic factors.
20) There-
fore, it may be important to identify patients at risk of LV re-
modeling to prevent LV dilation after AMI. 
Dyslipidemia is a well-established risk factor for coronary 
artery disease, but few information is available on its effects 
on microvascular perfusion. Experimental studies showed 
that independent of coronary artery stenosis severity, dyslip-
idemia may reduce myocardial flow reserve and capillary 
Table 4. Angiographic parameters of left ventricular dilatations 
and medication in patients with acute myocardial infarction
 
Group I
(n=154)
Group II
(n=604)
p
Thrombolysis (%) 017 (11.2) 54 (8.9) 0.255
Stenting (%) 109 (70.7) 395 (65.4) 0.148
Pre-PCI TIMI flow (≤2) (%) 114 (77.5) 396 (72.3) 0.035
Post-PCI TIMI flow (≤2) (%) 03 (1.9) 22 (3.6) 0.054
Multi-vessel involvement (≥2) (%) 068 (44.1) 283 (46.8) 0.306
LAD involvement (%) 094 (61.1) 315 (60.2) 0.267
Restenosis on follow–up CAG (%) 021 (20.1) 57 (9.4) 0.126
ACEI or ARB (%) 058 (38.1) 220 (36.5) 0.576
Statin (%) 047 (30.6) 191 (31.7) 0.617
Beta bloker (%) 066 (42.5) 162 (26.8) 0.122
PCI: percutaneous coronary intervention, TIMI: thrombolysis in 
myocardiacl infarction, LAD: left anterior descending artery, CAG: 
coronary angiography, ACEI: angiotensin converting enzyme in-
hibitor, ARB: angiotensin receptor bloker
Table 5. Predictors of progressive left ventricular dilatation by 
multivariate analysis
RR CI p
Age 0.850 0.554-1.305 0.457
Gender (male) 0.836 0.538-1.299 0.425
Dyslipidemia 1.559 1.035-2.347 0.030
Low ejection fraction (<45%) 3.328 2.099-5.276 0.008
Wall motion score index ≥1.5 2.142 0.008-0.192 0.033
Multi vessel involvement  0.765  0.519-1.128 0.177
Pre-PCI TIMI flow (≤2) 1.412 0.903-2.236 0.129
Post-PCI TIMI flow (≤2)  0.658 0.134-3.228 0.606
PCI: percutaneous coronary intervention, TIMI: thrombolysis in 
myocardiacl infarction
Fig. 1. A: left ventricular end diastolic volume (LVEDV) and end systolic volume (LVESV) at admission and 6-month were significantly increased 
in group I, and not in group II (black line: group I; dot line: group II; triangle: LVEDV; circle: LVESV). B: serial changes of left ventricular ejection 
fraction (LVEF) at admission and 6-month showed decreased LVEF in group I and no significant change in group II (black line: group I; dot line: 
group II). C: serial changes of total wall motion score (TWMS) at admission and 6-month demonstrated decreased TWMS in group II and 
no significant change in group I (black line: group I; dot line: group II).
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density, and may increase capillary endothelial cell apoptosis 
following ischemia and reperfusion, thus contributing to re-
duced LV function after AMI.
21)22) Among the clinical risk fac-
tor criteria, only the incidence of dyslipidemia was significantly 
higher in the LV dilatation group (p<0.05), whereas there were 
no statistical differences between groups in the other risk fac-
tors. Our data showed that dyslipidemia affected indepen-
dent progressive LV dilation after 6 months in AMI patients. 
Treatment of dyslipidemia may reduce microvascular perfu-
sion and myocardial salvage after AMI, and improve LV remo-
deling. 
Studies have showed that inflammatory cytokines were in-
volved in the process of LV remodeling after AMI, anti-in-
flammation treatment ameliorated LV remodeling and im-
proved cardiac performance. Hydroxymethylglutary coen-
zyme A reductase inhibition (statins) could affect the express-
ion of inflammatory cytokines.
23)24) Therefore, treatment of 
dyslipidemia with statins may helpful to reduce progressive 
LV dilatation. If we recorded lipid levels one or two months 
after discharge, it would be more helpful to understand LV 
progression pattern. Unfortunatelly, we do not have sufficient 
data of the follow up lipid levels one or two months after AMI.
According to early reports, a major determinant of ventri-
cular remodeling following AMI could be infarct size.
25) Myo-
cyte injury markers such as cardiac troponin I and T, CK and 
CK-MB appear to be useful in predicting late ventricular di-
lation. Anterior myocardial infarction, perfusion status of the 
culprit lesion, and CHF on admission are major predictors 
of LV dilation.
26)27) Several studies showed an association be-
tween elevated blood glucose at admission and subsequent 
adverse events, such as CHF, cardiogenic shock, and death.
28) 
Recently, hs-CRP, BNP and cardiac troponin I have been ex-
amined as potential predicting biomarkers of LV remodel-
ing.
29) High WMSI and markedly increased cardiac enzymes 
suggest large infarction. As mentioned above, our study show-
ed high wall motion score and low EF affected progressive 
LV dilatation. The mean values of hs-CRP and BNP were in-
creased in the LV dilatation group, consistent with the out-
comes of previous studies. However, there was no statistical 
significance demonstrated. 
Early reperfusion treatment improves survival by limiting 
infarct size and consequently preserving LV function. Early 
reperfusion therapy and patency of the IRA is crucial for re-
ducing infarct expansion and LV enlargement. Some inves-
tigators have tested the hypothesis that LV remodeling oc-
curs after percutaneous coronary intervention (PCI), despite per-
sistent patency of the IRA, and may influence the prognosis.
30)
Some reports showed Post-PCI TIMI grade was signifi-
cantly related to the change in LVEDVI and left ventricular 
end-sistolic volume index after 9 month.
30) But our data had 
no significance of post TIMI flow. 
The limitation of our study was a lack of knowledge of long 
term patency of the IRA because we did not perform rou-
tine follow-up coronary angiography. We only performed 
follow-up coronary angiography on 365 patients (48.1%). AMI 
patients with dyslipidemia, low EF and high wall motion sc-
ore at admission should be carefully monitored by clinical and 
serial echocardiographic examinations, which should serve 
helpful guidance to prevent or reverse LV remodeling.
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